Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 7.85% | 14.17% | -2.96% | -69.27% | -62.64% |
| Total Depreciation and Amortization | 76.69% | 82.71% | 51.27% | -30.69% | -18.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -60.36% | -70.69% | -66.09% | 273.30% | 177.32% |
| Change in Net Operating Assets | 159.44% | -59.73% | 116.43% | -1.34% | 18.35% |
| Cash from Operations | 7.92% | -12.56% | -10.11% | -34.92% | -30.41% |
| Capital Expenditure | -- | -- | 96.20% | 96.20% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.22% | 39.88% | 601.45% | 961.68% | 817.07% |
| Cash from Investing | 13.20% | 39.86% | 621.73% | 937.00% | 3,508.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 550.60% | -59.14% | -98.75% | -100.00% | -97.15% |
| Repurchase of Common Stock | 97.97% | 97.78% | 98.12% | -2,546.23% | -1,028.65% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 548.96% | -68.65% | -99.00% | -100.04% | -97.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 156.63% | 54.02% | -141.30% | -17.98% | -1,640.41% |